Transaction
Suzhou Vigonvita Life Sciences completed a new series of equity financing, with Qihoo 360, Share Venture, Ganzhou Qizhi Huikang, and Suzhou Meilingge becoming new shareholders of the company and the registered capital increasing to RMB5,769,231. Established in 2013, Vigonvita now has six innovative drugs in development, with the product fastest in the progress being TPN171. TPN171 is a selective PDE5 inhibitor sourced from flavonoid natural products, which is used to treat erectile dysfunction and pulmonary arterial hypertension.
Sep. 2
CanSino Biologics announced it initiated the phase III clinical trial for its Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (the “Ad5-nCoV”); the company entered into an agreement with NPO Petrovax Pharm, pursuant to which both parties will cooperate to conduct the phase III clinical trial for Ad5-nCoV in Russia; they have received the clinical trial application approval from the Ministry of Health of the Russian Federation. In addition, the company is currently driving the international multi-center phase III clinical trial for Ad5-nCoV and plans to conduct the phase III clinical trial for Ad5-nCoV in several countries.
Sep. 1
Gilead announced an agreement with Jounce Therapeutics to obtain an exclusive license to develop the latter’s JTX-1811 program. Under the terms of the agreement, Gilead will make a USD85 million upfront payment to, and a USD35 million equity investment at a premium in, Jounce upon closing. In addition, Jounce may receive up to an additional USD685 million in future clinical, regulatory and commercial milestone payments. JTX-1811 is a monoclonal antibody designed to selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells.
Salubris announced that it would transfer a total of 52,300,800 of the company’s unrestricted tradable shares (accounting for 5% of the company’s total stock capital) to CLSA Asset Management Limited by agreement at a price of RMB33.94/share for a total transfer price of more than RMB1.775 billion. The reason for the share transfer according to the announcement was that Carlyle Group highly recognized the team and product layout of Salubris.
Aug. 24
Escugen Biotech has announced the completion of pre-series A financing of tens of millions of RMB recently, which was funded by DT Capital and Cash Capital, etc. Escugen Biotech is an R&D enterprise of innovative antibodies, with products in development positioned as the best / first-in-class, and product lines having both druggability and market potential.
Bio-Thera announced an authorization, distribution and supply agreement with BeiGene to license the related intellectual property and product rights and interests in China of BAT1706 (bevacizumab) to BeiGene for a price. According to the agreement, the total of the upfront payment and milestone payments in this transaction can reach up to USD165 million, including an upfront payment of USD20 million, milestone payments of accumulatively not more than USD145 million, and royalties of a double-digit percentage.
Aug. 25
Bristol Myers Squibb (BMS) and Forbius jointly announced a definitive agreement under which BMS will acquire Forbius. Under this transaction, BMS will acquire Forbius’s TGF-beta program, including the program’s lead investigational asset, AVID200. AVID200 is a highly potent and isoform-selective TGF-beta inhibitor.
Aug. 31
Livzon Group announced a Patent Transfer and Technology Exclusive Licensing Agreement with TYK Medicines to obtain an exclusive right to develop and commercialize TY2136b (a ROS1/NTRK/ALK multiple target kinase inhibitor) and its relevant patents in the People’s Republic of China (including the Hong Kong, S.A.R., China Special Administrative Region, the Macau, S.A.R., China Special Administrative Region, and Taiwan, China) for not more than RMB151 million.
Aug. 13
Lerming Pharma announced a global strategic cooperation agreement with Ascendia Pharmaceuticals, a U.S. pharmaceutical company, to obtain the right to develop, produce and commercialize in the Chinese mainland the latter’s clopidogrel nanoemulsion (ASD-002) in development.
Aug. 11
Arctic Vision announced an exclusive license agreement with U.S...
(All Rights Reserved)